

Innovation all for the patients



Roche A member of the Roche group

Roche Announces Vabysmo's Long-Term Diabetic Macular Edema Study Data

TOKYO, July 18, 2024 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced that [F. Hoffmann-La Roche Ltd](#) (Head Office: Basel, Switzerland. CEO: Thomas Schinecker) issued a Media Release today, regarding four-year data from the RHONE-X extension study of Vabysmo[®] (generic name: faricimab) in diabetic macular edema (DME).

Please refer to the link below for details of the Roche's Media Release:

Roche's Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study

<https://www.roche.com/media/releases/med-cor-2024-07-17b>

###